OncoSec Medical Inc

NASDAQ:ONCS   4:00:00 PM EDT
2.55
-0.02 (-0.78%)
7:03:56 PM EDT: $2.51 -0.04 (-1.57%)
Regulatory, Earnings Announcements

Oncosec Announces Positive Clinical Data Of Keynote-695 Trial Assessing Tavo-Ep In Combination With Pembrolizumab

Published: 11/11/2022 14:36 GMT
OncoSec Medical Inc (ONCS) - Oncosec Announces Positive Clinical Data of the Keynote-695 Trial Assessing Tavo-ep in Combination With Pembrolizumab (keytruda®) in Patients With Advanced Melanoma Refractory to Anti-pd-1 Treatment.
Oncosec Medical - Top-line Results of Primary Endpoint of Keynote-695 Trial, Orr by Bicr Based on Recist V1.1, Expected to Be Announced in Q1 of 2023.
Oncosec Medical Inc - Key Secondary Endpoint of Keynote-695 Was Met.
Oncosec Medical Inc - Combination Therapy Was Generally Well Tolerated With No Grade 4/5 Treatment-related Adverse Events (traes).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$3.72

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$28.90

More details on our Analysts Page.